A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

January 22, 2025

Study Completion Date

January 22, 2025

Conditions
Endometrial CancerEndometrial Cancer RecurrentLung Cancer RecurrentLung CancerNon-small Cell Lung Cancer MetastaticNon-small Cell Carcinoma
Interventions
DRUG

RGX-104

DRUG

Ipilimumab

DRUG

Docetaxel

DRUG

Pembrolizumab

DRUG

Carboplatin

DRUG

Pemetrexed

Trial Locations (21)

10032

Columbia University Medical Center, New York

19107

Thomas Jefferson University Hospital, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

21044

Maryland Oncology, Columbia

22031

Virginia Cancer Specialists, PC, Fairfax

32799

Florida Cancer Specialist, Lake Mary

33709

Comprehensive Hematology Oncology, St. Petersburg

37203

The Sarah Cannon Research Institute, Nashville

40202

James Graham Brown Cancer Center, Louisville

55101

Regions Hospital, Saint Paul

70121

Ochsner Clinic Foundation, New Orleans

73104

OU Health Stephenson Cancer Center, Oklahoma City

80045

University of Colorado, Aurora

80218

Rocky Mountain Cancer Centers, Denver

Sarah Cannon Research Institute, Denver

85711

Arizona Oncology, Tucson

87505

Quantum Santa Fe, Santa Fe

90048

Cedars-Sinai Medical Center, Los Angeles

97239

Oregon Health Sciences University, Portland

03756

Dartmouth Hitchcock Medical, Lebanon

08901

CINJ, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Inspirna, Inc.

INDUSTRY

NCT02922764 - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | Biotech Hunter | Biotech Hunter